First Patient Dosed in CANbridge’s CAN-008 Phase I/II Trial in Newly-diagnosed Glioblastoma Multiforme in Taiwan First CANbridge Clinical Trial

CANbridge Signs Agreement with Boehringer Ingelheim to Manufacture Inhibitory Antibody,CAN-017,for Esophageal Squamous Cell Cancer

CANbridge’s CAN-008 Approved for Phase I/II Trial in Newly-Diagnosed Glioblastoma Multiforme in Taiwan

CANbridge Appoints Dr. Huai Zhong Hu as Vice President of Preclinical Development

CANbridge Life Sciences ltd. Elected to be a Member of Phirda

James Xue, Founder and CEO of CANbridge, Present at 2016 Boston CEO Conference

CANbridge Submits Investigational New Drug Application to Taiwan Food and Drug Administration for CAN-008 Phase I/II Trial in Glioblastoma Selects WuXi Biologics to Manufacture CAN-008 for the China Market

AVEO and CANbridge Life Sciences Announce Exclusive Licensing Agreement for AV-203 Outside of North America

CANbridge Completes Chinese Glioblastoma Biomarker Study for Lead Candidate, CAN008 Plans to Initiate Phase I/II Trial in Taiwan in 2016